This issue is to introduce the selective P2X3 receptor antagonist BLU-5937 developed by BELLUS Health Company of Canada. At present, it is about to carry out clinical phase III to treat the king of long-term cough-cough for more than 8 weeks. After standardized examination and treatment, refractory chronic cough with cough not relieved. According to statistics, the incidence of chronic cough in China is about 8.4, and there is a lack of effective treatment drugs in clinical practice. In January this year, the world's first drug with the same target developed by Merck Sa Dong went on the market, and the same target projects of many enterprises at home and abroad are also advancing rapidly. According to Bellus's public information, the BLU-5937 clinical results show obvious advantages in curative effect and adverse reactions compared with other similar projects/products.